FDA to make de­ci­sion about Karuna's schiz­o­phre­nia drug by next Sep­tem­ber

The FDA is set to de­cide whether to ap­prove Karuna Ther­a­peu­tics’ schiz­o­phre­nia drug by Sept. 26, the Boston biotech said Wednes­day be­fore the mar­kets opened.

The agency’s ac­cep­tance of Karuna’s ap­pli­ca­tion for KarXT, sub­mit­ted in late Sep­tem­ber, marks a mile­stone in the neu­ro­science R&D field. If the agency ap­proves the oral med­ica­tion, then Karuna would mar­ket the first new type of schiz­o­phre­nia drug in decades. It could be a megablock­buster, with Mizuho Se­cu­ri­ties an­a­lysts peg­ging KarXT’s peak sales po­ten­tial at more than $6 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER